BACKGROUND: For patients with chronic, non-cancer pain, traditional pain-relieving medications include opioids, which have shown benefits but are associated with increased risks of addiction and adverse effects. Medical cannabis has emerged as a treatment alternative for managing these patients and there has been a rise in the number of randomized clinical trials in recent years; therefore, a systematic review of the evidence was warranted.

OBJECTIVE: To analyze the evidence surrounding the benefits and harms of medical cannabinoids in the treatment of chronic, non-cancer-related pain.

DESIGN: Systematic review with meta-analysis.

DATA SOURCES: Medline, Embase, CINAHL, SCOPUS, Google Scholar, and Cochrane Databases.

ELIGIBILITY CRITERIA: English language randomized clinical trials of cannabinoids for the treatment of chronic, non-cancer-related pain.

DATA EXTRACTION AND SYNTHESIS: Study quality was assessed using the Cochrane risk of bias tool. All stages were conducted independently by a team of 6 reviewers. Data were pooled through meta-analysis with different durations of treatment (2 weeks, 2 months, 6 months) and stratified by route of administration (smoked, oromucosal, oral), conditions, and type of cannabinoids.

MAIN OUTCOMES AND MEASURES: Patient-reported pain and adverse events (AEs).

RESULTS: Thirty-six trials (4006 participants) were included, examining smoked cannabis (4 trials), oromucosal cannabis sprays (14 trials), and oral cannabinoids (18 trials). Compared with placebo,
cannabinoids showed a significant reduction in pain which was greatest with treatment duration of 2 to 8 weeks (weighted mean difference on a 0-10 pain visual analogue scale -0.68, 95% confidence interval [CI], -0.96 to -0.40, \( I^2 = 8\% \), \( P < .00001 \); n = 16 trials). When stratified by route of administration, pain condition, and type of cannabinoids, oral cannabinoids had a larger reduction in pain compared with placebo relative to oromucosal and smoked formulations but the difference was not significant (\( P[\text{interaction}] > .05 \) in all the 3 durations of treatment); cannabinoids had a smaller reduction in pain due to multiple sclerosis compared with placebo relative to other neuropathic pain (\( P[\text{interaction}] = .05 \)) within 2 weeks and the difference was not significant relative to pain due to rheumatic arthritis; nabilone had a greater reduction in pain compared with placebo relative to other types of cannabinoids longer than 2 weeks of treatment but the difference was not significant (\( P[\text{interaction}] > .05 \)). Serious AEs were rare, and similar across the cannabinoid (74 out of 2176, 3.4%) and placebo groups (53 out of 1640, 3.2%). There was an increased risk of non-serious AEs with cannabinoids compared with placebo.

CONCLUSIONS: There was moderate evidence to support cannabinoids in treating chronic, non-cancer pain at 2 weeks. Similar results were observed at later time points, but the confidence in effect is low. There is little evidence that cannabinoids increase the risk of experiencing serious AEs, although non-serious AEs may be common in the short-term period following use.

© The Author(s) 2020.

KEYWORDS: Cannabinoids; chronic pain; multiple sclerosis

PMID: 32127750  PMCID: PMC7031792  DOI: 10.1177/1179544120906461

Free PMC Article

Images from this publication. See all images (2) Free text

Conflict of interest statement

Publication type